{
  "id": 7505812,
  "title": "Deutsche Bank upgrades AstraZeneca stock rating to hold on trial results",
  "url": "https://urgent.news/2026/09/15/deutsche-bank-upgrades-astrazeneca-stock-rating-to-hold-on-trial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-15T08:08:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/deutsche-bank-upgrades-astrazeneca-stock-rating-to-hold-on-trial-results-93CH-4900936"
  },
  "original_language": "en",
  "account": "Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold and increased its price target to £117.00 from £115.00, following negative results from the SERENA4 trial. This comes nearly a year after the downgrade, which coincided with a report on breast cancer research. AstraZeneca shares dropped about 3% since then, lagging behind the European large-cap peer group by roughly 10% when adjusted for foreign exchange rates. Over the last six months, the stock has declined 13%, but it currently trades at a P/E ratio of 24.43 and a PEG ratio of 0.94. The downgrade was attributed to factors such as the second-half event overhang and patent cliff concerns, while other developments like Wainua and Bristol Myers Squibb were not anticipated. Deutsche Bank believes the risk-reward profile for AstraZeneca shares is now more neutral. In other developments, AstraZeneca's breast cancer drug Etcamah did not meet its primary goal in a late-stage clinical trial, while a combined treatment with Amgen showed promise in treating extensive-stage small-cell lung cancer. Additionally, AstraZeneca's Tezspire met its primary and secondary endpoints in a trial for eosinophilic esophagitis. However, their experimental silencer drug targeting ATTR-CM failed in a Phase 3 clinical trial, raising concerns in the pharmaceutical industry. Analyst activity includes RBC Capital initiating coverage with an Outperform rating and a price target of £145, highlighting potential growth despite recent challenges.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "FXStreet",
        "title": "Equities: AI slowdown fears hit chip stocks – Deutsche Bank",
        "url": "https://urgent.news/2026/09/15/equities-ai-slowdown-fears-hit-chip-stocks-deutsche-bank",
        "published": "2026-09-15T06:39:40.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}